OBLN - Obalon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2018-12-30
2017-12-30
2016-12-30
Total Revenue
4,530
9,101
9,914
3,393
Cost of Revenue
3,827
5,423
4,829
2,809
Gross Profit
703
3,678
5,085
584
Operating Expenses
Research Development
7,739
10,697
10,647
9,872
Selling General and Administrative
19,879
29,946
28,829
10,217
Total Operating Expenses
27,618
40,643
39,476
20,089
Operating Income or Loss
-26,915
-36,965
-34,391
-19,505
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-94
-189
-239
-485
Income Before Tax
-27,519
-37,380
-34,765
-20,467
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-27,519
-37,380
-34,765
-20,467
Net Income
-27,519
-37,380
-34,765
-20,467
Net Income available to common shareholders
-27,519
-37,380
-34,765
-20,467
Reported EPS
Basic
-
-19.60
-20.80
-48.50
Diluted
-
-19.60
-20.80
-48.50
Weighted average shares outstanding
Basic
-
1,904
1,672
422
Diluted
-
1,904
1,672
422
EBITDA
-
-36,384
-34,061
-19,313